Among all the advances in psychiatric pharmacology over the past two decades, SPRAVATO® stands out as the only FDA-approved esketamine product specifically developed for treatment-resistant depression — and for a subset of patients, it has represented a turning point after years of inadequate response to conventional antidepressants. At Wholistic Health in Mobile, Alabama, our team is certified to provide SPRAVATO® under the strict REMS program requirements established by the FDA, bringing this breakthrough treatment to Gulf Coast patients who have previously had to travel far from home to access it. Understanding what SPRAVATO® is, who it’s appropriate for, and what the treatment experience involves is essential before making any decisions about care.
What Is SPRAVATO® and Who Is It For?
SPRAVATO® is the brand name for esketamine nasal spray, developed by Janssen Pharmaceuticals. It is derived from ketamine but is a distinct drug — not interchangeable with IV ketamine — and carries its own separate FDA approvals. SPRAVATO® is FDA-approved for two specific indications: treatment-resistant depression (TRD) in adults who have not responded to at least two different antidepressants, and major depressive disorder with acute suicidal ideation or behavior (MDD with ASIB). These are precise, regulated indications, and SPRAVATO® is prescribed within them. It is not available for general depression or as a first-line treatment, and our team carefully evaluates every patient’s eligibility before beginning a SPRAVATO® treatment course.
If you are wondering what other options exist for depression treatment in Mobile, AL, our clinic offers several evidence-based and innovative approaches tailored to each patient’s history and needs.
The REMS Program and In-Clinic Administration
Because SPRAVATO® carries risks of dissociation, perceptual disturbances, and blood pressure changes, it is administered exclusively under a restricted FDA program called the Risk Evaluation and Mitigation Strategy, or REMS. This means that SPRAVATO® cannot be taken home. Every treatment session takes place at our certified Wholistic Health facility in Theodore, where clinical staff administer the nasal spray and monitor the patient for at least two hours following each dose. Transportation arrangements are required for every session — patients cannot drive themselves after SPRAVATO® administration. This structured monitoring environment exists to protect patient safety and is a non-negotiable part of the treatment protocol.
Treatment Schedule and Antidepressant Coordination
The treatment schedule for SPRAVATO® follows an FDA-approved protocol. During the induction phase — the first four weeks — patients receive two sessions per week. During the maintenance phase, sessions are reduced to once weekly for an additional four weeks, and then transitioned to once every one or two weeks depending on clinical response and physician recommendation. SPRAVATO® is always used in conjunction with a newly initiated or optimized oral antidepressant — it is not used as a monotherapy. Our team coordinates the antidepressant component of care to ensure that both elements of the regimen are working together appropriately.
Insurance Coverage: A Key Distinction from IV Ketamine
What distinguishes SPRAVATO® from IV ketamine is not just the route of administration but the regulatory context. SPRAVATO® is FDA-approved for TRD and MDD with ASIB — which means it is covered by Medicare and most commercial insurance plans for patients who meet those specific diagnostic criteria. This is a meaningful distinction from IV ketamine, which is used off-label and is rarely covered by insurance. Many of our patients at Wholistic Health who might otherwise be unable to access a ketamine-based treatment financially are able to pursue SPRAVATO® through their insurance benefits. Our team verifies coverage before beginning treatment and helps patients understand their expected out-of-pocket costs.
To learn more about how esketamine relates to other ketamine-based options, our post on how Spravato works provides a detailed pharmacological overview that many patients find helpful before their first consultation.
Side Effects and What to Expect During Sessions
The most commonly reported side effects of SPRAVATO® include dissociation, dizziness, nausea, sedation, and a feeling of intoxication or unreality during the monitoring period. For most patients, these effects resolve within two hours and are most intense immediately after the dose. Our clinical staff is trained to support patients through the monitoring period, and many find that with preparation and a calm environment, the experience becomes more manageable with each session. Results vary by individual — some patients experience rapid improvement in mood within the first one to two sessions, while others see gradual benefit accumulate over several weeks of consistent treatment.
SPRAVATO® vs. IV Ketamine: Clearing Up the Confusion
One barrier we encounter when discussing SPRAVATO® with patients is confusion about how it relates to IV ketamine. These are not the same medication, even though they share a pharmacological lineage. SPRAVATO® is esketamine — one enantiomer of ketamine — delivered as a nasal spray at a specific dose, within a regulated monitoring protocol, and approved for defined psychiatric indications. IV ketamine is racemic ketamine administered intravenously in a clinical setting, used off-label for psychiatric conditions. They have overlapping but not identical effects and different regulatory statuses. Our team takes time to explain this distinction clearly, because patients making informed decisions about their care deserve a clear picture of what each option involves.
For a broader understanding of ketamine-based options, our ultimate guide to ketamine therapy for depression walks through the full landscape of available treatments and how providers evaluate candidacy.
Addressing the Time Commitment
Another barrier is the time commitment. Twice-weekly appointments for the first four weeks, followed by weekly and then biweekly sessions, can feel daunting for patients who are managing work, family responsibilities, and the daily toll of treatment-resistant depression. We offer early morning and afternoon scheduling options to accommodate working adults, and our team communicates proactively about what to expect at each phase so that patients can plan around their sessions. We also recognize that the weight of depression itself can make maintaining appointments feel like a challenge, and we check in with patients between sessions to offer support and address any barriers to continued care.
Understanding how depression impacts day-to-day functioning — including motivation and follow-through — is something we cover in depth in our post on how depression affects the brain, which helps contextualize why consistent treatment engagement can be so difficult and why our team’s proactive support matters.
SPRAVATO® Is Not Experimental — It’s FDA-Approved and Insurance-Accessible
For patients in Mobile, Theodore, and the surrounding Gulf Coast region who have been living with treatment-resistant depression and have not yet heard about SPRAVATO®, we want to make it clear that this is not an experimental treatment — it is an FDA-approved, insurance-covered option that has been available since 2019 and has been used successfully for thousands of patients across the country. If you meet the diagnostic criteria and have documented treatment-resistant depression, you deserve to know this option exists and to have a qualified team evaluate whether it’s right for your specific situation.
Frequently Asked Questions
What is the difference between SPRAVATO® and IV ketamine?
SPRAVATO® (esketamine nasal spray) is FDA-approved for treatment-resistant depression and MDD with ASIB, and it is covered by most insurance plans. IV ketamine is used off-label for psychiatric conditions and is typically not covered by insurance. While they share a pharmacological relationship, they are distinct medications with different formulations, dosing, and regulatory contexts.
Is SPRAVATO® covered by insurance?
SPRAVATO® is covered by Medicare and most commercial insurance plans for patients who meet the FDA-approved indications — treatment-resistant depression or MDD with acute suicidal ideation or behavior. Our team verifies insurance eligibility before beginning treatment.
Can I take SPRAVATO® at home?
No. SPRAVATO® is only available through the FDA REMS program and must be administered and monitored in a certified healthcare setting. Patients must remain under clinical observation for at least two hours after each dose and cannot drive themselves home.
How quickly does SPRAVATO® start working?
Some patients notice improvements in mood within the first one to two sessions. For others, the benefit accumulates gradually over several weeks of consistent treatment. Results vary by individual, and response should be evaluated in partnership with your clinical team throughout the treatment course.
Do I need to stop my current antidepressant to take SPRAVATO®?
No. SPRAVATO® is always used alongside an oral antidepressant — not as a standalone treatment. Our team typically initiates or optimizes an oral antidepressant in conjunction with the start of SPRAVATO® therapy.
Key Takeaways
- SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation or behavior — it is a distinct drug from IV ketamine and has its own regulatory status.
- SPRAVATO® is covered by Medicare and most commercial insurance plans for patients who meet diagnostic criteria.
- Every SPRAVATO® session takes place at our certified facility with a mandatory two-hour monitoring period — it cannot be taken home.
- SPRAVATO® is always used alongside an oral antidepressant and is not a standalone therapy.
- Results vary by individual — some patients see rapid improvement while others experience gradual benefit over the full treatment course.
Conclusion
For Gulf Coast patients who have exhausted multiple antidepressants without finding the relief they deserve, SPRAVATO® offers a well-established, FDA-approved, and insurance-accessible path forward. Our team at Wholistic Health is here to evaluate your eligibility, guide you through the REMS process, and provide the clinical support that makes every phase of SPRAVATO® treatment as effective and comfortable as possible. Schedule a consultation and discuss with your provider whether SPRAVATO® is the right next step in your treatment-resistant depression care.
About Wholistic Health Team
The clinical team at Wholistic Health in Theodore, AL brings specialized expertise in treatment-resistant mental health conditions — including harm OCD and other presentations — offering exposure and response prevention therapy, SSRI management, and IV ketamine therapy for patients who have not responded to first-line care. The team approaches disclosures with clinical understanding and zero judgment, recognizing that the distress-to-intent ratio — not the content of intrusive thoughts — is the key diagnostic signal. Weekend appointments and phone consultations are available to reduce scheduling barriers, with transparent cost discussions from the first contact to ensure logistical concerns do not delay patients from getting the care they need. Learn more on our About Us page.
References
FDA SPRAVATO® Approval — https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-search
Janssen SPRAVATO® Prescribing Information — https://www.spravato.com/
American Journal of Psychiatry — https://ajp.psychiatryonline.org/
National Institute of Mental Health — https://www.nimh.nih.gov/health/topics/depression
Medical Disclaimer
This blog post is intended for educational purposes only and does not constitute medical advice. SPRAVATO® is FDA-approved for specific indications only — treatment-resistant depression and MDD with acute suicidal ideation or behavior. Results vary by individual, and no specific outcome is guaranteed. Please discuss with your provider whether SPRAVATO® is appropriate for your specific health situation before making any medical decisions.